Atossa rises as FDA lifts clinical hold on breast cancer study

Atossa Therapeutics

24/10/2022 17:07

** Shares of drug developer Atossa Therapeutics  ATOS.O  up
1.1% at 83 cents 
    ** ATOS says U.S. Food and Drug Administration lifted
clinical hold and allowed co to begin mid-stage study of its
drug candidate endoxifen  urn:newsml:reuters.com:*:nGNX68KrwG 
    ** ATOS will be testing endoxifen in premenopausal women
with a certain type of early-stage breast cancer
    ** Adds that co is discontinuing its AT-301 COVID-19 program
to focus on its breast cancer study
    ** As of last close, stock down ~47% YTD
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))